Rede D'Or São Luiz (RDOR3) investor relations material

Executive summary

• Achieved record gross revenue of R$9.9 billion in Q2 2026, up 9.9% year-over-year, with strong growth in surgeries and oncology services, and net income rising 9.7% to R$1.2 billion.

• EBITDA reached R$2.9 billion, up 18.2% year-over-year, with margin improvement and robust operational efficiency.

• SulAmérica reported net revenue of R$8.7 billion, up 6.9% year-over-year, with a 53.4% increase in EBITDA and improved loss ratio.

• Operations span hospital services, insurance, private pension, and asset management, with 76 hospitals and over 10,000 beds.

• Recognized for sustainability and quality, with multiple international awards and expansion of the hospital network.

Financial highlights

• Consolidated gross revenue reached R$16.0 billion in Q2 2026, up 5.9% year-over-year; six-month consolidated net revenue was R$29.0 billion, up from R$26.9 billion.

• Oncology gross revenue in Q2 2026 was R$1.149 billion, up 22.3% year-over-year, with a 15.2% rise in infusion volume and a 6.1% higher average ticket.

• Surgical volume reached 151,000 in Q2 2026, up 10.6% year-over-year; elective surgeries grew 11.5% and made up 72.8% of total.

• Gross profit rose 20.1% year-over-year to R$2.3 billion, with gross margin expanding by 2.3 percentage points.

• Cash flow for the semester was R$5.4 billion, representing a 92.2% EBITDA conversion rate.

Outlook and guidance

• Continued focus on operational efficiency, procurement, and technology, with over 20 expansion projects expected to deliver 2,690 new beds between 2026 and 2028.

• Ongoing investments in greenfield and brownfield projects, with significant works nearing completion in key hospitals.

• Management expects further growth in patient volumes and service mix, especially in oncology and elective procedures.

• No explicit forward-looking financial guidance provided, but management remains optimistic about sustaining growth and profitability.